ISRG
JNJ
A little analyst optimism, with a catch
Evercore ISI didn’t exactly go full cheerleader here. It kept Intuitive Surgical at In Line and left the price target at $480, but it did add the stock to its Tactical Outperform List ahead of earnings. Translation: not a long-term thesis makeover, more like a “we like the setup for the next lap” kind of call.
Why the stock might have some juice
The firm’s logic is pretty straightforward: procedure growth could come in stronger than Wall Street expects. Evercore estimated first-quarter 2026 procedure growth at about 16.5%, roughly 200 basis points above Street estimates. If you toss in Ion biopsy procedures, it thinks total growth could clear 17%. That’s the kind of surprise that can turn an earnings print from meh to hey, not bad.
Investors are staring at the low end of the range
ISRG has already slid 17% year to date and is hanging around the low end of its $450 to $600 trading range over the last year. So if earnings show the business is still humming, the market may decide it’s time to stop treating the stock like it forgot how to run.
The bigger picture
There’s also a little background noise working in ISRG’s favor: Johnson & Johnson just beat expectations in its surgical franchise, which Evercore is using as a confidence boost for procedure trends more broadly. Add in upbeat chatter from other analysts — including Buy calls from TD Cowen and Freedom Capital Markets — and you’ve got a stock that’s not exactly unloved, just under a microscope.
Big picture: this isn’t a buy-the-whole-company thesis bombshell. It is, however, a nicely timed setup for earnings — and in markets, timing can matter almost as much as the story.